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Background/aim: Human parvovirus B19 is a pathogen that affects different parts of the body. We planned this study because of the
lack of data on B19 seroprevalence based on different body-system diseases.
Materials and methods: The prevalence of parvovirus B19 antibodies was investigated retrospectively in 1239 patients by review
of medical records from 2009–2012, according to their diseases classified under general titles in compliance with the International
Classification of Diseases (ICD-10). Parvovirus B19-specific antibodies were detected by quantitative enzyme immunoassays.
Results: The positivity rate was 27.8% for only IgG, 8.5% for only IgM, and 2.6% for both IgG and IgM. The highest positivity for IgG
alone was found in musculoskeletal system and connective tissue diseases (55.9%), while the highest positivity for IgM was found in
neoplasms (16.4%). The highest positivity for IgG was seen in rheumatoid arthritis (72.2%) and pregnancy (52.6%), and the highest
positivity for total IgM was found in upper respiratory tract disease (21.0%) and hepatic failure (17.1%).
Conclusions: Parvovirus B19 seroprevalence was relatively low in northeastern Anatolia compared to most serological studies conducted
in other regions. We think that this study has provided the first wide-ranging information on the seroprevalence of B19 in diseases and
disorders of the major human body systems.
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1. Introduction
Human parvovirus B19 (B19), frequently seen all over
the world, is a pathogenic agent associated with various
diseases and disorders that affect different body systems.
Erythema infectiosum, chronic arthritis, spontaneous
abortion, hematological disorders, myocarditis, and
glomerulonephritis are only some of these (1–3). B19 is
spread from person to person by infected respiratory
secretions, by infected blood and blood-product
transfusions, and by vertical transmission from mother to
fetus (4,5).
B19-specific IgM antibodies appear 10–12 days after
exposure to the virus and may be detected in serum for
3–6 months. IgG antibodies appear after approximately 2
weeks and persist for life (6). The prevalence of antibodies
to B19 has been reported at higher rates in studies carried
out in different geographic regions. Approximately 15% of
preschool children, 50% of adults, and 85% of the elderly
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are seropositive (7). B19-specific IgG antibody prevalence
varies worldwide, ranging from 2% to 15% in children
aged 1–5 years and from 30% to 60% in adults (8).
From the discovery of B19 until the present day,
large numbers of studies have been done to clarify its
relationship with various diseases. In Turkey the number
of studies on the seroprevalence of B19 is very low and
most of the publications are case reports. Also, although
B19 is recognized as a pathogen associated with many
diseases and disorders of various tissues and organs,
there is no comprehensive report on its seroprevalence
in human body systems in Turkey and around the world.
To address this deficiency and provide input to the
literature, we systematically evaluated the seroprevalence
of B19 antibodies in major disease groups classified by
the International Classification of Diseases (ICD-10), as
well as several specific diseases and symptoms of patients
admitted to our hospital.
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2. Materials and methods
2.1. Study populations
In this study, 1239 serum samples belonging to different
patients (658 men and 581 women) with various diseases
were evaluated retrospectively for B19 IgG and IgM
antibodies. The study was performed on serum samples
sent to our laboratory from various clinics at Atatürk
University Research Hospital in Erzurum, Turkey, in
2009–2012. The clinical data for the diagnosis of diseases
were obtained from medical records. The defined diseases
were collected by us under general headings in accordance
with the categories of the ICD-10 (9).
2.2. Detection of antibodies to parvovirus B19
PVB19-specific IgG and IgM antibodies were detected
with quantitative enzyme immunoassays (NovaLisa
Parvovirus B19 IgG/IgM-ELISA; Dietzenbach, Germany).
In calculating the antibody prevalence, samples with a cutoff value of 10 NovaTec units or above were considered.
2.3. Statistical analysis
Statistical analysis was done using the Pearson chi-square
test in 2 × 2 tables. When the P-value was less than 0.05,
the differences between the variables were considered
to be statistically significant. All statistical analysis was
performed using IBM SPSS Statistics for Windows, version
20.0 (IBM Corp., Armonk, NY, USA).
3. Results
3.1. B19 serology according to patient characteristics
The results of B19 serology in 1239 patients according
to sex and age groups are summarized in Table 1. B19
antibodies were detected in 38.9% of the patients. Three

hundred and forty-four patients (27.8%) had only IgG
antibodies, 106 (8.5%) had only IgM antibodies, and
32 (2.6%) had both types of antibodies. When patients
positive for both IgG and IgM antibodies were included,
the seropositivity rate increased to 30.3% for IgG and to
11.1% for IgM. IgG and/or IgM antibodies were positive in
244 of 581 women (42.0%) and in 238 of 658 men (36.2%).
The seroprevalence among females was significantly
higher than in males (P = 0.036). The total IgM positivity
showed no significant difference between males (72/658)
and females (66/581) (P = 0.816). The seropositivity of IgG
antibodies was significantly higher for 1-year-old children
(38/161) compared to 2-year-olds (25/167) (P = 0.047).
The prevalence of IgG antibodies showed a tendency to
increase after the age of 6 years. When the positivity of
this antibody in adults aged 18 and over (64/124) was
compared with the positivity in children aged 17 and
younger (312/1115), the results were extremely statistically
significant (P < 0.000).
3.2. B19 serology in disease groups by ICD-10
According to the results obtained from the medical
records, 820 of 1239 patients (no diagnosis was noted in
the remaining 419 cases) were collected under 13 main
disease headings of the ICD-10, as shown in Table 2. The
highest positivity for B19 IgG antibody alone was detected
in diseases of the musculoskeletal system and connective
tissues and during pregnancy, childbirth, and puerperium
(PCP). When B19 IgG and IgM antibodies were positive
together in the same patient, the highest positivity for B19
IgM antibodies was detected in neoplasms. Total positivity
of IgG plus IgM antibodies was calculated to be highest

Table 1. Results of B19 serology in 1239 patients according to sex and age.
Variables

n

IgG (+)

IgM (+)

IgG (+) IgM (+)

Total

Female

581

178 (30.6)

46 (7.9)

20 (3.5)

244 (42.0)

Male

658

166 (25.3)

60 (9.1)

12 (1.8)

238 (36.2)

1 year

161

37 (23.0)

14 (8.7)

1 (0.6)

52 (32.3)

2 years

167

23 (13.8)

13 (7.8)

2 (1.2)

38 (22.8)

3 years

75

9 (12.0)

11 (14.7)

2 (2.6)

22 (29.3)

4 years

69

13 (18.8)

8 (11.6)

1 (1.5)

22 (31.9)

5 years

66

14 (21.2)

7 (10.6)

1 (1.5)

22 (33.3)

6 years

61

15 (24.6)

5 (8.2)

1 (1.6)

21 (34.4)

7–11 years

289

88 (30.4)

26 (9.0)

12 (4.2)

126 (43.6)

12–17 years

227

87 (38.3)

21 (9.3)

6 (2.6)

114 (50.2)

≥18 years

124

58 (46.8)

1 (0.8)

6 (4.8)

65 (52.4)

Total

1239

344 (27.8)

106 (8.5)

32 (2.6)

482 (38.9)

Sex

Age group

Data presented as n (%) of patients.
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Table 2. Results of B19 serology in disease groups by ICD-10.
Disease category by ICD

n

IgG (+)

IgM only/or together
with IgG (+)

Total

Diseases of musculoskeletal and connective tissues

59

33 (55.9)

6 (10.2)

39 (66.1)

Diseases of the digestive system

54

22 (40.7)

8 (14.8)

30 (55.5)

Diseases of the skin and subcutaneous tissue

31

13 (41.9)

4 (12.9)

17 (54.8)

Pregnancy, childbirth, and puerperium

19

10 (52.6)

-

10 (52.6)

Neoplasms

67

22 (32.8)

11 (16.4)

33 (49.2)

Diseases of the blood and blood-forming organs

104

35 (33.7)

14 (13.5)

49 (47.1)

Endocrine, nutritional, and metabolic diseases

62

21 (33.9)

8 (12.9)

29 (46.8)

Diseases of the nervous system

46

18 (39.1)

3 (6.5)

21 (45.6)

Symptoms, signs, and abnormal clinical and
laboratory findings, not elsewhere classified

196

43 (21.9)

29(14.8)

72 (36.7)

Diseases of the genitourinary system

63

19 (30.1)

3 (4.8)

22 (34.9)

Diseases of the respiratory system

75

14 (18.7)

11 (14.7)

25 (34.9)

Certain infectious and parasitic diseases

24

5 (20.8)

3 (12.5)

8 (33.3)

Diseases of the circulatory system

20

4 (20.0)

2 (10.0)

6 (30.0)

Unspecified patients

419

85 (20.3)

36 (8.6)

121 (28.9)

Data presented as n (%) of patients.

in diseases of the musculoskeletal system and connective
tissues, diseases of the digestive system, diseases of the
skin and subcutaneous tissues, and during PCP.
3.3. B19 serology in specific diseases
Results of B19 serology in specific diseases or disorders
that involve 15 or more patients are given in Table 3. The
highest total seropositivity was detected in rheumatoid
arthritis and hepatic failure. These were followed by acute
lymphadenitis, juvenile arthritis, malnutrition, epilepsy,
leukemia, malignant neoplasms, and other diseases. The
highest positivity was detected in rheumatoid arthritis for
IgG and in upper respiratory infections for IgM.
4. Discussion
Detection of B19 IgG and IgM antibodies in a serum
sample is generally sufficient in order to understand the
course of parvoviral diseases. A positive IgM result in the
presence or absence of IgG antibodies reflects an acute
infection, and a positive IgG result in the absence of IgM
antibodies is indicative of past B19 infection (10).
The prevalence of these antibodies varies from region
to region. In Turkey, the prevalence of the B19 IgG
antibody has been reported in 38.6% of randomly selected
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children aged 4–6 years in Antalya (11), in 26.9% of
children under the age of 15 and 54.5% of adults over the
age of 20 with a presumptive diagnosis of B19 infection
in İstanbul (12), and in 20.7% of children admitted to
hospital aged 0–17 years and 36.0% of healthy adults in the
Central Anatolia region (13). In our study representing the
Northeast Anatolia region, overall seropositivity of B19
IgG antibodies was 33.7% in children aged 0–17 years and
51.6% in adults. According to the results, the prevalence
of B19 IgG in Turkey ranges from approximately 21% to
39% in children younger than 18 years and approximately
36% to 55% in adults. This wide variation could be due
to differences in the numbers, health status, sex, and age
of patients, and to the possible differences in susceptibility
of used tests and differences in the years of studies. B19
prevalence rates reported in studies conducted in other
countries also differ from each other. Röhrer et al. (14),
in a study in Germany, found a seroprevalence of IgG in
adults aged 18 and up of 72.1%, and of 47.6% at 2–18 years.
In this study, positivity of IgG antibodies in women was
slightly significantly higher than in men (73.4% vs. 70.8%,
respectively). In a study conducted in India, Kishore et al.
(15) reported that seroprevalence of B19 in adult blood
donors increased with age and the overall seroprevalence
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Table 3. B19 serology in specific diseases or disorders.
Disease

n

IgG (+)

IgM only/or together
with IgG (+)

Total

Rheumatoid arthritis

18

13 (72.2)

-

13 (72.2)

Hepatic failure (acute/chronic)

41

19 (46.3)

7 (17.1)

26 (63.4)

Acute lymphadenitis

23

10 (43.5)

3 (13.0)

13 (56.5)

Juvenile rheumatoid arthritis

16

7 (43.8)

2 (12.5)

9 (56.3)

Malnutrition

28

13 (46.4)

2 (7.1)

15 (53.6)

Epilepsy

22

10 (45.5)

1 (4.5)

11 (50.0)

Leukemia and malignant neoplasms

55

19 (34.5)

8 (14.5)

27 (49.0)

Anemia

37

13 (35.1)

3 (8.1)

16 (43.2)

Fever of unknown origin

64

16 (25.0)

10 (15.6)

26 (40.6)

Acute tonsillitis

24

5 (20.8)

4 (16.7)

9 (37.5)

Acute upper respiratory infections

19

3 (15.8)

4 (21.0)

7 (36.8)

Abdominal and pelvic pain

132

27 (20.4)

19 (14.4)

46 (34.8)

Urinary tract disorders

44

12 (27.3)

3 (6.8)

15 (34.1)

of the antibody was 39.9%, higher in males than in females
(44% vs. 27%, respectively). Su et al. (16), in Taiwan,
reported that overall seroprevalence of B19 IgG in healthy
volunteers was 23.1%, that the positive rate of the antibody
increased slightly with age, and that the antibody rate was
slightly higher in men than in women (27.8% vs. 18.8%,
respectively). The antibody positivity detected in our study
was lower than in all of the other studies (excluding the
Taiwan study).
It has been shown that the B19 IgG antibody seropositive
rate varies depending on age, location, season, sex, and
time of the last B19 epidemic (8,17). To reach a more
satisfying conclusion, comparisons of epidemiological
studies conducted in different locations should be made,
taking into account all of these factors. Unfortunately, that
is not always possible for several reasons, such as a limited
number of studies on the subject, an insufficient number
of cases, and the absence or lack of similar cases.
In our study, the highest positivity for B19 antibodies
was found in diseases of the musculoskeletal and connective
tissues, diseases of the digestive system, diseases of the skin
and subcutaneous tissues, and during PCP, followed by the
other diseases. The antibody positivity in unspecified cases
was found to be lower than in all of the specified diseases.
However, seropositivity of parvoviral antibodies is
considerably varied in the same or different human bodysystem diseases. This situation has been observed in other
studies. For example, for diseases of the musculoskeletal

and connective tissues, a German study by Weissbrich et
al. (18) showed that seroprevalence of B19 IgG in children
affected by juvenile idiopathic arthritis was 31.3% in earlyonset pauciarticular arthritis, 39.5% in reactive arthritis,
57.1% in unclassified arthritis, and 62.4% in arthralgia. In
a study conducted in the Central Anatolia region in Turkey
by Us et al. (19), IgG and IgM positivity were reported to
be 52.9% and 1.1% in rheumatoid arthritis and 64.0% and
2.0% in systemic lupus erythematosus, respectively. Türk
Dağı et al. (20) detected B19 IgG in 85 of 114 patients with
rheumatoid arthritis and 29 of 46 healthy persons, and
they reported that the difference of B19 IgG frequencies in
these groups was not statistically significant. In our study,
the antibody prevalence was found to be 72.2% in adults
with rheumatoid arthritis and 43.8% in children with
juvenile rheumatoid arthritis. Likewise, in association
with diseases of the blood and blood-forming organs, and
in disorders involving the immune mechanism, a study
conducted in Tunisia by Regaya et al. (21) showed that B19
IgG antibody positivity was 56.5% in patients with sickle
cell anemia and 39.1% in patients with beta thalassemia.
In Nigeria, IgG and IgM antibody positivity was 61.6%
and 17.8%, respectively, in sickle cell anemia. Iwalokun
et al. (22) detected B19 IgM and IgG antibodies in 17.8%
and 61.6%, respectively, of sickle cell anemia patients.
B19 IgG and IgM antibody positivity in Kenyan children
with severe anemia was found by Wildig et al. (23) to
be 14.8% and 3.7%, respectively. The prevalence rates of
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IgG in pregnancy among studies conducted in different
countries vary widely. In studies of pregnant women,
Ghazi (24) reported B19 IgG seroprevalence at 46.6% in
Saudi Arabia, and Jensen et al. (25) reported it at 66%
in Denmark. We found a 52.6% prevalence of B19 IgG
seropositivity among pregnant women. In India, Kishore
et al. (26) found that the B19 IgG antibody prevalence
was 34.3% in children with hematologic malignancies
such as leukemia and lymphoma, which are contained in

the neoplasm group. This rate is very close to the value
obtained for leukemia and malignant neoplasms in our
study. There are limited studies on the seroepidemiology
of B19 in the literature related to other body systems and
tissues, and most of these are case reports and molecular
studies.
Therefore, we think that the current study contributes
to the literature related to the seroprevalence of B19 in
diseases or disorders of the major human body systems.
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